Vivani Medical, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Rule 10b5-1 Trading Plan Disclosure.
On July 8, 2024, Lisa Porter, the Company’s Chief Medical Officer, entered into a 10b5-1 trading plan. Dr. Porter’s plan provides for the sale of up to 93,000 shares of the Company’s common stock. Sales of the shares of the Company’s common stock set forth in Dr. Porter’s trading plan, if any, will be made at or above specified market prices. The trading plan will expire on or before June 30, 2025. Dr. Porter’s trading plan was entered into during an open insider trading window and is intended to satisfy Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding insider transactions.
Apart from as disclosed above, no Rule 10b5-1 plans or non-Rule 10b5-1 trading arrangements were adopted, modified, or terminated by officers or directors of the Company, nor were there any material changes to the procedures by which security holders may recommend nominees to the Company’s Board of Directors, during the quarter ended December 31, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.